Opinion: Stop Private Speculation in COVID-19 Research

We present an economic plan for a collective sharing of scientific knowledge on the pandemic.

Written byEmiliano Brancaccio and Ugo Pagano
| 3 min read
coronavirus covid-19 sars-cov-2 economic patents shared open access research vaccine development

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, ANYAIVANOVA

The crisis triggered by the emergence of the SARS-CoV-2 coronavirus requires immediate leaps forward in economic policy strategies. In a document published in the Financial Times on March 13 we have underlined the urgency of international coordination to implement an immediate “anti-virus” plan in three points: immediate control of capital markets to counter speculation, public investments in health care and research, and interventions to remedy possible “disorganization” in the markets that could create bottlenecks in production and difficulties in supplying goods and services even beyond the health care sector.

Sharing scientific and technical knowledge publicly means winning the battle against the virus.

One aspect of this public planning seems particularly urgent to us. It is necessary to denounce the behavior of private agents driven by a profit motive who are causing slowdowns in research against the virus. There are private companies that announce impending discoveries in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies